Single nucleotide polymorphism: A new risk factor for endometrial cancer?

Future Oncology

Volumn 1, Issue 3, 2005, Pages 323-330

  Kang, Sokbom ^a   Roh, Ju Won ^b   Kim, Jae Weon ^c  

^a National Cancer Center   (South Korea)

^b Dongguk University   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

endometrial cancer; estrogen; germline mutation; p53; polymorphism

Indexed keywords

TUMOR PROTEIN;

ENDOMETRIUM TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 33646464423     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.1517/14796694.1.3.323     Document Type: Review

References (65)

1. Kaaks R, Lukanova A, Kurzer MS: Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol. Biomarkers Prev. 11(12), 1531-1543 (2002).
2. Swanson CA, Potischman N, Wilbanks GD et al.: Relation of endometrial cancer risk to past and contemporary body size and body fat distribution. Cancer Epidemiol. Biomarkers Prev. 2(4), 321-327 (1993).
3. Gruber SB, Thompson WD: A populationbased study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group. Cancer Epidemiol. Biomarkers Prev. 5(6), 411-417 (1996).
4. Parslov M, Lidegaard O, Klintorp S et al.: Risk factors among young women with endometrial cancer: a Danish case-control study. Am. J. Obstet. Gynecol. 182(1 Pt 1), 23-29 (2000).
5. Weber BL, Nathanson KL: Low penetrance genes associated with increased risk for breast cancer. Eur. J. Cancer 36(10), 1193-1199 (2000).
6. Setiawan VW, E Hankinson S, A Colditz G, Hunter DJ, Vivo ID: Estrogen receptor (ESR2) polymorphisms and endometrial cancer (United States). Cancer Causes Control 15(6), 627-633 (2004).
7. Berstein LM, Imyanitov EN, Gamajunova VB et al.: CYP17 genetic polymorphism in endometrial cancer: are only steroids involved? Cancer Lett. 180(1), 47-53 (2002).
8. Berstein LM, Imyanitov EN, Kovalevskij AJ et al.: CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity. Cancer Lett. 207(2), 191-196 (2004).
9. Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N, Dahiya R: CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor á and estrogen receptor expressions. Cancer Res. 63(14), 3913-3918 (2003).
10. Haiman CA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I: A polymorphism in CYP17 and endometrial cancer risk. Cancer Res. 61(10), 3955-3960 (2001).
11. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J: Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis 18(12), 2307-2311 (1997).
12. McGrath M, Hankinson SE, Arbeitman L, Colditz GA, Hunter DJ, De Vivo I: Cytochrome P450 1B1 and catechol-Omethyltransferase polymorphisms and endometrial cancer susceptibility. Carcinogenesis 25(4), 559-565 (2004).
13. Weiderpass E, Persson I, Melhus H, Wedren S, Kindmark A, Baron JA: Estrogen receptor á gene polymorphisms and endometrial cancer risk. Carcinogenesis 21(4), 623-627 (2000).
14. Sugawara T, Nomura E, Sagawa T, Sakuragi N, Fujimoto S: CYP1A1 polymorphism and risk of gynecological malignancy in Japan. Int. J. Gynecol. Cancer 13(6), 785-790 (2003).
15. Berstein LM, Imyanitov EN, Suspitsin EN et al.: CYP19 gene polymorphism in endometrial cancer patients. J. Cancer Res. Clin. Oncol. 127(2), 135-138 (2001).
16. Sasaki M, Kaneuchi M, Fujimoto S, Tanaka Y, Dahiya R: CYP1B1 gene in endometrial cancer. Mol. Cell Endocrinol. 202(1-2), 171-176 (2003).
17. De Vivo I, Huggins GS, Hankinson SE et al.: A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc. Natl Acad. Sci. USA 99(19), 12263-12268 (2002).
18. Duguay Y, McGrath M, Lepine J et al.: The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res. 64(3), 1202-1207 (2004).
19. Setiawan VW, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I: HSD17B1 gene polymorphisms and risk of endometrial and breast cancer. Cancer Epidemiol. Biomarkers Prev. 13(2), 213-219 (2004).
20. Iwamoto I, Fujino T, Douchi T, Nagata Y: Association of estrogen receptor á and 3- adrenergic receptor polymorphisms with endometrial cancer. Obstet. Gynecol. 102(3), 506-511 (2003).
21. Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N, Dahiya R: Polymorphisms of estrogen receptor á gene in endometrial cancer. Biochem. Biophys. Res. Commun. 297(3), 558-564 (2002).
22. Hachiya T, Kuriaki Y, Ueoka Y, Nishida J, Kato K, Wake N: WAF1 genotype and endometrial cancer susceptibility. Gynecol. Oncol. 72(2), 187-192 (1999).
23. Roh JW, Kim JW, Park NH et al.: p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol. Oncol. 93(2), 499-505 (2004).
24. Agorastos T, Masouridou S, Lambropoulos AF et al.: p53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur. J. Cancer Prev. 13(4), 277-280 (2004).
25. Peller S, Halperin R, Schneider D, Kopilova Y, Rotter V: Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol. Rep. 6(1), 193-197 (1999).
26. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J: Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P450 (CYP1A1) loci. Br. J. Cancer 75(9), 1385-1388 (1997).
27. Ueda M, Hung YC, Terai Y et al.: Glutathione S-transferase GSTM1, GSTT1 and p53 codon 72 polymorphisms in human tumor cells. Hum. Cell 16(4), 241-251 (2003).
28. Black D, Bogomolniy F, Robson ME, Offit K, Barakat RR, Boyd J: Evaluation of germline PTEN mutations in endometrial cancer patients. Gynecol. Oncol. 96(1), 21-24 (2005).
29. Paynter RA, Hankinson SE, Hunter DJ, De Vivo I: No association between MTHFR 677 C?T or 1298 AC polymorphisms and endometrial cancer risk. Cancer Epidemiol. Biomarkers Prev. 13(6), 1088-1089 (2004).
30. Han J, Hankinson SE, Zhang SM, De Vivo I, Hunter DJ: Genetic variations in XRCC2 and XRCC3 are not associated with endometrial cancer risk. Cancer Epidemiol. Biomarkers Prev. 13(4), 330-331 (2004).
31. Kouji B, Nobuyuki S, Takeshi H et al.: Identification of germline MSH2 gene mutations in endometrial cancer not fulfilling the new clinical criteria for hereditary nonpolyposis colorectal cancer. Cancer Genet. Cytogenet. 146(1), 58-65 (2003).
32. Lane DP: Cancer. p53, guardian of the genome. Nature 358, 15-16 (1992).
33. El-Deiry WS, Tokino T, Velculescu VE et al.: WAF1, a potential mediator of p53 tumor suppression. Cell 75(4), 817-825 (1993).
34. Honda T, Kato H, Imamura T et al.: Involvement of p53 gene mutations in human endometrial carcinomas. Int. J. Cancer 53(6), 963-967 (1993).
35. Kihana T, Hamada K, Inoue Y et al.: Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients. Cancer 76(1), 72-78 (1995).
36. Niwa K, Murase T, Morishita S, Hashimoto M, Itoh N, Tamaya T: p53 overexpression and mutation in endometrial carcinoma: inverted relation with estrogen and progesterone receptor status. Cancer Detect. Prev. 23(2), 147-154 (1999).
37. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV: Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell Biol. 7(2), 961-963 (1987).
38. Lukas J, Groshen S, Saffari B et al.: WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am. J. Pathol. 150(1), 167-175 (1997).
39. Chedid M, Michieli P, Lengel C, Huppi K, Givol D: A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene 9(10), 3021-3024 (1994).
40. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W: Hormonal interactions in endometrial cancer. Endocr. Relat. Cancer 7(4), 227-242 (2000).
41. Sherman ME: Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod. Pathol. 13(3), 295-308 (2000).
42. Enmark E, Pelto-Huikko M, Grandien K et al.: Human estrogen receptor -gene structure, chromosomal localization, and expression pattern. J. Clin. Endocrinol. Metab. 82(12), 4258-4265 (1997).
43. Lecce G, Meduri G, Ancelin M, Bergeron C, Perrot-Applanat M: Presence of estrogen receptor in the human endometrium through the cycle: expression in glandular, stromal, and vascular cells. J. Clin. Endocrinol. Metab. 86(3), 1379-1386 (2001).
44. Yaich L, DuPont WD, Cavener DR, Parl FF: Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Res. 52(1), 77-83 (1992).
45. Westberg L, Baghaei F, Rosmond R et al.: Polymorphisms of the androgen receptor gene and the estrogen receptor gene are associated with androgen levels in women. J. Clin. Endocrinol. Metab. 86(6), 2562-2568 (2001).
46. Comings DE: Polygenic inheritance and micro/minisatellites. Mol. Psychiatry 3(1), 21-31 (1998).
47. Forsell C, Enmark E, Axelman K et al.: Investigations of a CA repeat in the oestrogen receptor gene in patients with Alzheimers disease. Eur. J. Hum. Genet. 9(10), 802-804 (2001).
48. Lau HH, Ho AY, Luk KD, Kung AW: Estrogen receptor gene polymorphisms are associated with higher bone mineral density in premenopausal, but not postmenopausal southern Chinese women. Bone 31(2), 276-281 (2002).
49. Sundarrajan C, Liao WX, Roy AC, Ng SC: Association between estrogen receptor- gene polymorphisms and ovulatory dysfunctions in patients with menstrual disorders. J. Clin. Endocrinol. Metab. 86(1), 135-139 (2001).
50. Zheng SL, Zheng W, Chang BL et al.: Joint effect of estrogen receptor sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women. Cancer Res. 63(22), 7624-7629 (2003).
51. Carey AH, Waterworth D, Patel K et al.: Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum. Mol. Genet. 3(10), 1873-1876 (1994).
52. Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF: Catechol-O- methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wildtype and variant COMT isoforms. Cancer Res. 61(18), 6716-6722 (2001).
53. Li J, Yen C, Liaw D et al.: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947 (1997).
54. Cantley LC, Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl Acad.Sci. USA 96(8), 4240-4245 (1999).
55. Steck PA, Pershouse MA, Jasser SA et al.: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet. 15(4), 356-362 (1997).
56. Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J: Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57(17), 3660-3663 (1997).
57. Kim SK, Su LK, Oh Y, Kemp BL, Hong WK, Mao L: Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines. Oncogene 16(1), 89-93 (1998).
58. Risinger JI, Hayes AK, Berchuck A, Barrett JC: PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 57(21), 4736-4738 (1997).
59. Tashiro H, Blazes MS, Wu R et al.: Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 57(18), 3935-3940 (1997).
60. Obata K, Morland SJ, Watson RH et al.: Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 58(10), 2095-2097 (1998).
61. Liaw D, Marsh DJ, Li J et al.: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genet. 16(1), 64-67 (1997).
62. De Vivo I, Gertig DM, Nagase S et al.: Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers. J. Med. Genet. 37(5), 336-341 (2000).
63. Sun H, Enomoto T, Fujita M et al.: Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am. J. Clin. Pathol. 115(1), 32-38 (2001).
64. Hornreich G, Beller U, Lavie O, Renbaum P, Cohen Y, Levy-Lahad E: Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol. Oncol. 75(2), 300-304 (1999).
65. Levine DA, Lin O, Barakat RR et al.: Risk of endometrial carcinoma associated with BRCA mutation. Gynecol. Oncol. 80(3), 395-398 (2001).